Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
yea, and with a forecast like that, it seems like an easy process..
Take a position, do nothing, make money... I think that will work.
Quanta for 2021 will be undergoing a name change to be announced shortly as well as Quanta is in the process of expanding its product line from 4 SKUs to 38 by summer. We will also be introducing all new branding with new color schemes, new packaging, and exciting celebrity endorsements for the pain relief products and a newly introduced beauty product line. Quanta will also be working on a men’s cosmetic line in conjunction with one of the celebrity endorsements planned for late 2021. The company has hired an advertising agency to help with the rollout of the new branding expected second quarter 2021. This will work in conjunction with a major push the company is on the path of with some major big box retail chains.
From now on it is bid support on the dips until this whole plan comes together, which I am estimating will be about two years.
For those that understand the potential of this industry they should also understand the entire potential of their suppliers, their technology and the future of this industry..
I just wiped out everything under .083, thank you!!!
About time, mergers are now at a snails pace.
Let's get out of toe rag city here, one good PR and the flip terds will be gone and we can make real money here..
within two years this should reach full value.
Medolife Rx to Present at The 2021 Sequire Cannabis Conference on Tuesday, April 20, at 3 p.m. EST/12 p.m. PST
BURBANK, Calif., April 15, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that Quanta’s President and Director Philip Sands will be presenting virtually at a cannabis investing conference, the 2021 Sequire Cannabis Conference, on Tuesday, April 20, at 3 p.m. EST/12 p.m. PST.
Sands will discuss how Medolife Rx and Quanta will continue to develop their positions in the bioceutical space. He will further discuss their cutting-edge technology, pharmaceutical research, and the development of consumer wellness products for the CBD industry. Additionally, he will address how the Company is planning to develop pharmaceutical-grade CBD products lines for which it will seek clinical regulatory approvals, focusing on indications such as pain.
Nah, this is not my first rodeo. I know what's coming little grasshopper.
I'm in on that news, something much bigger in the shadows and I think I want to be part of it.. will take time to build a position but sometimes providing bid support is worthwhile.
SAINT JEAN CARBON PROVIDES UPDATE REGARDING TRANSACTION WITH SOLID ULTRABATTERYMarch 12, 2021, Calgary, Alberta, Canada – With reference to its prior news release dated February 10, 2021, Saint Jean Carbon Inc. (“Saint Jean” or the “Company”) (TSX-V: SJL) is pleased to announce that it is close to signing a definitive Share Exchange Agreement (the “Agreement”) dated March 9, 2021 with 2 arm’s length vendors to purchase all of the issued and outstanding shares of Solid Ultrabattery Inc. (“SUB”), a private Ontario company involved in the research and development of solid state batteries (the “Acquisition”). The terms of the Acquisition have been amended slightly in that Saint Jean intends to fund the purchase of all of the issued and outstanding shares of SUB by issuing 21 million common shares in the capital of the Company (the “Common Shares”), instead of the previously announced 20 million Common Shares, at a price of $0.06 per Common Shares, which is within the allowable discount permitted by the Policies of the TSX Venture Exchange (“TSX-V”), for a deemed aggregate purchase price of CAD $1,260,000. The proposed arm’s length Acquisition remains subject to the approval of the TSX-V.
professional money starting to take notice, should see significant blocks soon.
Probably has to do with this acquisition
Saint Jean Carbon Receives Conditional Approval For Acquisition of Solid Ultrabattery
April 8, 2021 11:37 am ET
Saint Jean Carbon Receives Conditional Approval For Acquisition of Solid Ultrabattery
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES
CALGARY, Alberta, April 08, 2021 (GLOBE NEWSWIRE) -- With reference to its prior news release dated February 10, 2021, March 12, 2021 and March 16, 2021, Saint Jean Carbon Inc. ("Saint Jean" or the "Company") (TSX-V: SJL) is pleased to announce that it has received conditional approval from the TSX Venture Exchange (the "TSX-V") for the purchase from 2 arm's length vendors of all of the issued and outstanding shares of Solid Ultrabattery Inc. ("SUB"), a private Ontario company involved in the research and development of solid state batteries (the "Acquisition"). Saint Jean intends to fund the purchase of all of the issued and outstanding shares of SUB by issuing 22 million common shares in the capital of the Company (the "Common Shares") at a price of $0.06 per Common Share for a deemed aggregate purchase price of CAD $1,320,000.
grasp the impact!!..
at one of the leading cancer research centers in the United States showing that the Company's lead drug candidate Escozine(R) caused up to 95 percent Specific Induced Apoptosis (SIA) in various types of Leukemia cancer cells. Such a result is significant not only to the Company's ongoing clinical research, but could have tremendous effects on cancer treatments worldwide.
nah, this is the only way companies can grow, it's only toxic if they do not have a game plan to buy out of it.. and they do.. watch and see.If they don't fly high within a year then the toxic becomes a bit of a pull down but not now. Fund a public company and expect to pay 30% on your money if you do not produce, been there done that many times.
Besides they are restricted 144 shares for 6 months ( 1 year if it was a shell) so I am not worried at all.. not at all.. actually a smart move.
great, now they will have some money for development, that is how the market works, go public to raise money for expansion.
It is still early in the reverse merger process, however share structure verification by a transfer agent is a requirement by FINRA if they want to complete the merger.
Transfer Agent Not Available
https://www.otcmarkets.com/stock/EMDF/security
you do not need to worry about a reverse split here, with this share structure they will need at least half the structure for build-out and overhead, that should balance out for some stable retail shares.
As of March 15, 2021, the issuer had 504,289,776 common shares, $0.0001 par value, issued and outstanding.
Dilution, that is another story, if they have to hit the toxic funding market then they better build out quickly. Ideally partner with a major of a happy life.
That often happens in reverse merger plays, the old stuckholders want to leave on the first glimpse of life... Better they go now then later, there was also an S-1 but that should be held for a while, maybe some will skim off but the big money has not found this yet...
Watch the authorized and make sure it does not go up too much, also the 10-k is late, that will answer all the questions from the past year. (The 10-k is the annual audited report)
Outstanding Shares 63,464,746 03/12/2021
thank you, another 100k shares in the till... this may turn into a great ride..
Medolife Rx Receives Significant Purchase Order of Immunapen, Its Easy-to-Use Nutraceutical Product Designed to Increase Quality of Life and Support a Healthy Immune System
BURBANK, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire – Medolife Rx, Inc. ("Medolife"), a global integrated bioceutical company with R&D, manufacturing, and consumer product distribution, which is a majority owned subsidiary of Quanta, Inc. (OTC PINK: QNTA), announced today that the Company has received a significant purchase order for its nutraceutical product Immunapen™, a consumer-facing product designed to increase the quality of life of users through enhancing their immune system. The order looks to propel the revenue generation side of the business, where the company sells nutraceutical and wellness products in high-impact areas such as pain management, sleep aid and immune system support.
The Immunapen™ is a natural homeopathic drug that is sold over the counter to general patient populations around the world. It is derived from the Company’s proprietary formulation found in its lead drug candidate Escozine®, which includes a small molecular peptide found in scorpions that is then polarized through a patented process. The formulation is designed to enhance the user’s immune system while providing an energy booster that increases the overall quality of life. Its new and improved pen design is easy-to-use and can be carried on the go.
The purchase order for 1,400 Immunapen™ Originals came from a pharmaceutical wholesaler based in the Republic of Armenia who will distribute the products throughout the region. This is the first purchase order from the wholesaler and the Company hopes that it will be the beginning of a strong relationship. The Company also has developed Immunapen™ Anti-Anxiety, Immunapen™ Sleep, and Immunapen™ Energy & Focus.
“Immunapen is a homeopathic solution that we are extremely proud of and prepared to produce on a mass scale as the world turns its attention to boosting the human immune system,” said Medolife CEO Dr. Arthur Mikaelian. “While we continue our clinical research efforts on Escozine as a drug therapeutic, we are also able to sell Immunapen as a nutraceutical, creating two paths for revenue generation and consumer adoption. Since the onset of the COVID-19 pandemic, we have seen a major increase in interest for immune system support in both the pharmaceutical and nutraceutical categories. After conducting significant pre-clinical research on Escozine, we verified its immune system support properties, which led us to producing this one-of-a-kind, easy-to-use product designed to support and increase quality of life in general patient populations. Although it contains some of the most expensive liquid material in the world, through our own facilities and manufacturing, we are able to produce the pens in an affordable way that makes them attractive to large distributors. We hope this is just the first of many purchase orders of the Immunapen product.”
The market for products that boost the immune system was already one of the strongest segments in functional foods and supplements. Consumers are turning to products that promise to improve their immune systems more than ever during the ongoing COVID-19 pandemic, with companies and brands around the world reporting significant sales spikes. Immune health is one of the top five reasons people take dietary supplements and global market sales of immune health supplements were valued at $14 billion in 2017 and is expected to reach $25 billion by 2025, according to a forecast by Persistence Market Research.
The Company recently announced the expansion of its first-of-its-kind scorpion reservation located in the Dominican Republic (“DR”). The facility allows the Company to safely and humanely cultivate scorpions of various types for the extraction of the peptides necessary to produce Escozine®, which is currently awaiting product registration for the treatment of the COVID-19 virus in the region, as well as its nutraceutical Immunapen™ product line.
Current Status: Project Sri Pada
Phase 2 drilling and construction of infrastructure has begun.
Bank feasibility & piloting complete on graphite
Off-take agreement in place valued at $200 million for material distribution
Off-take offers on the table via the Indian Market
Process flow-design complete
Construction Infrastructure phase has become
Solar Power Plant contract signed
construction teams mobilized
Infrastructure support application submitted to government
Asian development bank application started
This is a district scale opportunity
Well Yahh... If your going to buy a property take some core samples and send them to the lab to prove to your partners your not "salting the mine". That is not the same as a geologist taking control of a drill core when it is fresh out of the pipe...
We know there is a deposit, now the big money wants to know how big the deposit is, what is the mine life, and what is the payoff period.
The big money would want it to be publicly traded so there is a sense of value in their holdings.
What we know is we don't know.
nah, someone said and remote emails do not cut it, the actual name of the drilling company is what I was looking for..
I do not think the cores have been submitted yet.
so your saying the drill cores have already been done and sent to the lab??
Time is the enemy here, travel restrictions have put a hold on verifying the deposit.The 43-101 may not be completed before the third quarter of this year, they still need to drill the property and send the drill cores to the lab.. then the geologist (who ever he is) writes a report, usually a month for that, and no one knows who the drill team is yet..
Pre-announcement of going public is basically a quiet period, although usually someone gets thrown a bone for some glimmer of hope on a hope stock.
Mining stocks take time, two years is usually the magic number from discovery to verification..
sure if you could get 10 million shares at .001 you could be dillutionally confident too.
Quit hyping garbage
Those are 144 shares and have a 6 month mandatory hold period, besides these are long term holders.
WMHI...So Harry Zhang gave himself 100,000,000 shares at .001 when he came on board and this is where this new company is///
The company is looking for acquiring a viable operation.
That is a pathetic investment I will pass.
Well all right. It looks like the toe-rags have come and gone, raped pillaged and plundered and made their few cents per share. Now those of us that know how to make big money are standing around with our hands over our balls because we don't know what will happen next. Communication is the only answer here and unfortunately I am up to my eye balls in boxes because the penny market just changed my zip code.. I will make an attempt to get to the bottom of this holding but I am not worried too much because the drill team and independent geologist are still under CV-19 lock down.. The web site no longer says NI43-101 in Q2 so if that is not done by end of Q3 I would be a little nervous. If anyone has a good phone number I will take it, save me digging for it...If I have to call the dogs out to find a number I will do that too.. I hardly ever invest in foreign miners but this one has a US CEO
Now this is concerning to me and something I was not ware of,
but Mark would not answer the phone or emails from Ben.
could you fill me it.
Bringing a shell public is not that easy, where they usually bog down is money to pay the auditor and the accountant, and the big unknown, the legal fees needed to track down old restrictive shares that were never cashed, the list goes on. I might suggest you pick up the damn phone and chase him down if you are nervous..
ask him.
I tend to study mission statements, and when a pinky no information has a mission statement the same (ver bed um) as a growing private company well.... until that changes I remain invested.
https://www.amecamining.com/
https://www.otcmarkets.com/stock/STHC/profile
And there you go right there...the answer...
Simple deductive reasoning that is what you need to succeed in this game.
Ask yourself, if you were the CEO of a private mining company that needed 20 million to extract 20 billion worth of ore how would you go about doing it.. It is a very complicated and drawn out process but what is needed above all else is a verification of the deposit. That verification has internationally recognized parameters that must be met before regulatory and financial acceptance of the deposit.
Show me the drill cores,, I be happy.
Now the timeline to completion is going to get some gnashing of teeth around here, it is their timetable not yours.
I still have not figured out where to put bid support, maybe I wait a month.
4.5 mil traded and it is off the high, with that kind of news it really should go the other way. Either large positions giving it up, dilly lution, or dead money blues,
Just not sure, cannot still be too early here, maybe it is. Either way, I have a two year time frame on this one.
With the share structure that this one has it should climb in pps at an accelerated rate.
Outstanding Shares 63,464,746 03/12/2021
What we don't have is awareness... scorpion venom as a covid-19 savior will be a hard sell.
Unless you are aware that blue scorpion venom has been used for centuries by native people.
AND IT ACTUALLY WORKS!! They all take time, it will happen here.
They will need a 43-101 to qualify for the TSX. And for a project like this, the best and biggest money hangs with the TSX standards..
Is this company an explorer or a mine builder or a producer?
Big difference on their exit strategy but once they are fully compliant lets see what major raises their hand first.